NEOADJUVANT THERAPIES FOR BREAST CANCER HER-2 POSITIVE: EXPERIENCE IN THE HOSPITAL ONCOLOGICO GRAL. SOLON ESPINOSA AYALA

Leonardo David Villacres; Juan Reyes Villacreses; Victor Teran Perez; Yolanda Guzman Jordan; Carolina Saldana; Mayra Beltran Ortiz; Santiago Rivadeneira; Rene Munoz

Volume : VIII, Issue : IV, April - 2019

NEOADJUVANT THERAPIES FOR BREAST CANCER HER-2 POSITIVE: EXPERIENCE IN THE HOSPITAL ONCOLOGICO GRAL. SOLON ESPINOSA AYALA

Leonardo David Villacres, Juan Reyes Villacreses, Victor Teran Perez, Yolanda Guzman Jordan, Carolina Saldana, Mayra Beltran Ortiz, Santiago Rivadeneira, Rene Munoz

Abstract :

Objectives: to describe the demographic variables for east cancer HER-2 positive in neoadjuvant treatment and evaluate the response to trastuzumab compared to chemotherapy alone. Methods: a descriptive analysis of older women than 18 years old during the years 2010 and 2015 in which neoadjuvant chemotherapy was performed, evaluating the overall survival, the time of progression, the pathological response. The crossing of variables was performed using Chi-square, the survival estimate was made using the Kaplan Meier method and the survival functions were compared using the Log-Rank test. Results: The neoadjuvant treatment was performed in 35 patients with stages II (11/31.4%) and III (24/68.6%), a pathologic complete remission (pCR) was achieved in patients treated with trastuzumab in (13 / 44.8 %), without reaching a statistically significant level. With respect to the rCP in regard to the immunophenotype HER2 + versus HER2 + / HR=hormonal receptor (36.4 vs 37.5 months), with respect to survival, no statistically significant differences were obtained, however, general survival was obtained an average of 81.4 months Conclusion: although the main weakness of this study is that is a retrospective trial, in our institution with the TCH scheme we reached an acceptable rCP, so we are within the international standards in relation to the neoadjuvant, however, we must look for new Strategies such as sequential chemotherapy, double blockade of HER-2 and, in this way, improve the results.